2024澳门原料网站-免费完整资料

Be the most trusted biotech company

2021-04-22

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
2021-04-20

Application for Clinical Trial of Henlius Bevacizumab HLX04-O Has Been Approved for the Treatment of wAMD in Latvia
2021-04-15

Henlius Received IND Approval for Its Novel Anti-LAG-3 mAb HLX26 from NMPA
2021-04-14

First Subject Dosed in Phase 1 Clinical Trial of Henlius COVID-19 Drug Candidate HLX71 in the US
2021-03-29

Making Most out of Launched Products, Fueling Diversified Innovation through Integrated Platform
2021-03-28

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint
2021-03-19

Henlius Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD
2021-03-11

First Patient Dosed in Phase II/III Clinical Trial of Henlius Anti-PD-1 mAb HLX10 Combined with Bevacizumab for the First-line Treatment of mCRC
2021-01-29

Henlius Bevacizumab Has Received Clinical Trial Approval in Australia